ClinicalTrials.gg
RecruitingNCT07662395Updated Jun 23, 2026

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

A Phase 2/3 interventional study of SCTB41 and Tislelizumab in Double Blind, sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
277th of 1,593
410 · median 100
Started
2026
with 190 others
Phase 2/3
38 of 1,880
16 open now
Primary completion
2030-01
later than 932 of 986 live
Registered
1,803rd of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 277th largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 191 that started in 2026, is one of 38 in phase 2/3, reaches primary completion later than 932 of the 986 other live ones, and was the 1,803rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally advanced or metastatic non-small cell lung cancer (NSCLC).

The Phase II portion is an open-label safety run-in study enrolling approximately 30-60 patients to evaluate the safety and tolerability of SCTB41 plus chemotherapy. Following confirmation of acceptable safety and preliminary efficacy, the study will proceed to the Phase III portion.

The Phase III portion is a randomized, double-blind, active-controlled study enrolling approximately 350 patients. Eligible participants will be randomized in a 1:1 ratio to receive SCTB41 plus chemotherapy or tislelizumab plus chemotherapy. The primary objective is to compare progression-free survival assessed by blinded independent central review according to RECIST version 1.1.

Read the detailed description

The Phase II portion is an open-label safety run-in study enrolling approximately 30-60 patients to evaluate the safety and tolerability of SCTB41 plus chemotherapy. Following confirmation of acceptable safety and preliminary efficacy, the study will proceed to the Phase III portion.

The Phase III portion is a randomized, double-blind, active-controlled study enrolling approximately 350 patients. Eligible participants will be randomized in a 1:1 ratio to receive SCTB41 plus chemotherapy or tislelizumab plus chemotherapy. The primary objective is to compare progression-free survival assessed by blinded independent central review according to RECIST version 1.1.

03

Conditions studied

  • Double Blind

Keywords

  • Advanced Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • SCTB41
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written (ICF) signed prior to screening.
  2. Age ≥18 years, male or female.
  3. (ECOG) performance status of 0-1.
  4. Expected survival ≥3 months.
  5. or cytologically confirmed locally advanced (Stage IIIB/IIIC) or (Stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and is not suitable for definitive concurrent or sequential chemoradiotherapy, according to the 9th edition of the TNM staging system by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC).
  6. For subjects with adenocarcinoma, non-smokers, or squamous cell carcinoma with mixed adenocarcinoma components, absence of sensitizing EGFR mutations (e.g., exon 19 deletion, exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I) or ALK gene rearrangements must be confirmed by tumor tissue, cytology, or blood samples prior to enrollment.
  7. Availability of tumor tissue samples for testing.
  8. No prior systemic anticancer therapy for the study disease.
  9. At least one (excluding brain lesions) per v1.1. 10 Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Known ROS1 fusion-positive, BRAF V600E mutation, or other driver mutations for which guideline-recommended targeted therapies are available.
  2. Prior thoracic radiotherapy.
  3. Symptomatic central nervous system .
  4. Imaging evidence during screening showing tumor invasion of major blood vessels, invasion of critical surrounding organs, or risk of tracheoesophageal fistula or esophagopleural fistula as assessed by the investigator.
  5. History of hypertensive crisis or hypertensive encephalopathy, or uncontrolled hypertension despite medication.
  6. Active disease or a history of autoimmune disease with a risk of recurrence.
  7. Bleeding tendency, high bleeding risk, or coagulation disorders.
  8. Other .
  9. Active serious infection prior to first dose, including active infection, active tuberculosis, positivity, active or C, or known active syphilis.
  10. pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  11. History of non-infectious pneumonia requiring systemic therapy or current interstitial lung disease.
  12. Prior allogeneic organ transplantation or hematopoietic stem cell transplantation.
  13. Known allergy to any component of the drug(s), or history of severe reaction to any monoclonal antibody.
  14. Participation in another clinical trial, except for follow-up in observational (non-interventional) studies or follow-up phases of interventional studies.
  15. Pregnant or breastfeeding women.
  16. Known alcohol or drug abuse, psychiatric disorders, or history of illicit drug use.
  17. Any other condition deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    SCTB41 + Chemotherapy

    SCTB41 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Chemotherapy regimen will be selected by the investigator based on histological subtype: squamous NSCLC receives carboplatin + paclitaxel or nab-paclitaxel; non-squamous NSCLC receives pemetrexed + cisplatin or carboplatin. Combination therapy will be administered for 4 cycles , followed by maintenance therapy according to the protocol.

    Drug: SCTB41 · Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed

  • Active comparator
    Tislelizumab + Chemotherapy

    Tislelizumab will be administered at a dose of 200 mg intravenously (IV) every three weeks (Q3W). Chemotherapy regimen will be selected by the investigator based on histological subtype: squamous NSCLC receives carboplatin + paclitaxel or nab-paclitaxel; non-squamous NSCLC receives pemetrexed + cisplatin or carboplatin. Combination therapy will be administered for 4 cycles, followed by maintenance therapy according to the protocol.

    Drug: Tislelizumab · Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed

Interventions

  • DrugSCTB41

    IV infusion,Specified dose on specified days.

  • IV infusion,Specified dose on specified days.

  • 175 mg/m², IV infusion, Q3W, for 4 cycles.

  • 100 mg/m², IV infusion, on Days 1, 8, 15 of each 3-week cycle, for 4 cycles

  • AUC 5, IV infusion, Q3W, for 4 cycles.

  • 75 mg/m², IV infusion, Q3W, for 4 cycles.

  • 500 mg/m², IV infusion, Q3W, for 4 cycles .

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the blinded IRRC or death due to any cause (whichever occurs first).

    Time frame: Up to approximately 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2030, 44 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 23, 2026
StartActual
May 9, 2026
Primary completionEst.
Jan 24, 2030
CompletionEst.
Jan 24, 2030
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662395
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
May 9, 2026
Primary completion
Jan 24, 2030 (estimated)
Completion
Jan 24, 2030 (estimated)
Last update
Jun 23, 2026

Study contacts

yanyan yang, medical monitor
Contact
yanyan_yang@sinocelltech.com
+8618353576376

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SCTB41

Start the discussion